Pharma Focus Asia

08/10/2026

𝐓𝐡𝐞 𝐄𝐦𝐞𝐫𝐠𝐞𝐧𝐜𝐞 𝐨𝐟 𝟑𝐃 𝐏𝐫𝐢𝐧𝐭𝐢𝐧𝐠 𝐢𝐧 𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐚𝐧𝐝 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐂𝐨𝐦𝐩𝐨𝐮𝐧𝐝𝐢𝐧𝐠

In Pharma Focus Asia – Issue 64, Doug Zemba, CEO, and Andrew Klein, CTO of Additive Innovations LLC, explore how 3D printing is reshaping clinical research and pharmaceutical compounding through rapid formulation development, personalised dosing, and on-demand production of complex dosage forms.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How 3D printing shortens timelines in early-stage clinical research by enabling in-house production of test articles and eliminating the traditional development-to-production gap
• Technical and operational barriers to scaling patient-specific therapies, including awareness, experience, and material qualifications
• Current limitations in printable pharmaceutical-grade materials and how binder jetting with standard APIs and excipients is accelerating adoption
• The role of education and awareness in helping global regulators adapt frameworks for 3D-printed drug products
• Ensuring batch consistency, reproducibility, and quality control in flexible, decentralised manufacturing environments
• Impact of on-demand production on supply chains — reducing waste, improving access in remote areas, and managing inventory more efficiently
• How 3D printing accelerates adaptive clinical trials through rapid iteration of dosage forms and strengths
• Promising applications in complex drug delivery systems such as multilayered and controlled-release formulations
• Integration with digital health and AI to enable truly individualised therapies
• Transformation of traditional compounding practices in pharmacies and hospitals, and the infrastructure needed for adoption

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
As personalised medicine and complex therapies grow in importance, 3D printing offers a flexible, precise, and decentralised pathway to accelerate research, reduce waste, and deliver patient-specific treatments. From clinical prototyping to on-site compounding, it is opening new possibilities across the pharmaceutical value chain.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/expert-corner/the-emergence-of-3d-printing-in-expanding

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

07/10/2026

𝐖𝐡𝐲 𝐄𝐱𝐨𝐬𝐨𝐦𝐞 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 𝐀𝐫𝐞 𝐒𝐭𝐢𝐥𝐥 𝐅𝐚𝐫 𝐅𝐫𝐨𝐦 𝐭𝐡𝐞 𝐌𝐚𝐫𝐤𝐞𝐭

Extracellular vesicles (EVs), particularly exosomes, have emerged as promising therapeutic platforms for regenerative medicine, oncology and immunotherapy. Yet despite hundreds of clinical trials and encouraging early-stage results, no EV-based therapeutic product has reached the commercial market.

𝐀𝐮𝐭𝐡𝐨𝐫𝐬:
Dr Deepika Arora, Regenerative Cell Research Institute
Aditya Banerjee, Regenerative Cell Research Institute

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• The manufacturing gap holding back EV therapeutics
• Challenges in scaling cell culture for therapeutic quantities
• Moving from ultracentrifugation to scalable purification technologies
• The need for consistent quality control and standardised dosing
• Understanding exosome pharmacokinetics and biodistribution
• Advancing GMP-compliant manufacturing for commercial production
• Building a unified framework across biotech, CDMOs and regulators

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: The biggest challenge facing exosome therapeutics may no longer be proving their biological potential, but developing the manufacturing, purification, quality and regulatory infrastructure needed to turn that potential into safe, consistent and commercially viable medicines. Bridging this manufacturing gap could be critical to bringing the first EV-based therapeutic to market.

🔗 https://www.pharmafocusasia.com/articles/the-exosome-manufacturing-gap

Exosome manufacturing faces major GMP, scale-up and purification challenges, from bioreactor production and TFF to quality control and EV therapeutics.

07/10/2026

𝐀𝐈 𝐈𝐬 𝐢𝐧 𝐄𝐯𝐞𝐫𝐲 𝐏𝐡𝐚𝐫𝐦𝐚 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐲 𝐃𝐞𝐜𝐤. 𝐒𝐨 𝐖𝐡𝐲 𝐀𝐫𝐞 𝐃𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐒𝐭𝐢𝐥𝐥 𝐓𝐚𝐤𝐢𝐧𝐠 𝐒𝐨 𝐋𝐨𝐧𝐠?

In Pharma Focus Asia – Issue 64, Nagarajan Selvaraj, CEO of Seosaph Infotech and MD of VirtuNx, explores the gap between AI strategy and real-world decision-making in pharma, and why data readiness, integrated workflows, governance, and organisational alignment are essential for turning AI investments into enterprise-wide impact.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why AI investments are not always translating into faster, more confident business decisions
• How fragmented data ecosystems and legacy systems continue to slow AI adoption
• Why data consistency, context, and traceability are critical to building trust in AI
• The organisational and cultural barriers preventing AI from being embedded into high-stakes decisions
• How pharma companies can move AI from isolated pilots into core business workflows
• Why people, processes, and governance matter as much as technology when scaling AI
• How regulatory requirements can support trust, transparency, and responsible AI adoption
• Why AI must connect cross-functional insights to enable enterprise-level decision-making
• How pharma leaders can evolve KPIs to measure decision quality and speed, not just efficiency
• Why structuring decision-making itself may be the key to making AI a true decision engine

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
AI can generate powerful insights, but insights alone do not transform an organisation. In pharma, the real value of AI emerges when data, technology, people, processes, and governance come together at the point of decision. Structuring how decisions are made can create the foundation for AI to move beyond experimentation and become part of the enterprise operating model.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/expert-corner/ai-is-in-every-pharma-strategy-deck

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

06/10/2026

𝐅𝐫𝐨𝐦 𝐒𝐧𝐚𝐩𝐬𝐡𝐨𝐭𝐬 𝐭𝐨 𝐌𝐨𝐯𝐢𝐞𝐬: 𝐇𝐨𝐰 𝐀𝐈 𝐈𝐬 𝐔𝐧𝐥𝐨𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐂𝐨𝐧𝐭𝐢𝐧𝐮𝐨𝐮𝐬 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐉𝐨𝐮𝐫𝐧𝐞𝐲

In Pharma Focus Asia – Issue 64, Nader Alaghband, CEO of Ampersand Health, explores how AI, health apps, wearables, and connected technologies are helping pharmaceutical research move from episodic patient snapshots toward a more continuous understanding of disease and treatment response.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How smartphones, health apps, wearables, and connected devices are creating new streams of patient-generated health data
• Why continuous observation can reveal disease dynamics and residual burden that traditional clinical datasets may miss
• How AI can transform large-scale patient-generated data into meaningful scientific insight
• The potential for longitudinal data to deepen understanding of treatment response, adherence, persistence, and patient experience
• How continuous data could support the development of new digital endpoints and outcome measures
• Why data quality, representativeness, validation, governance, and scientific judgement remain essential

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
For decades, pharmaceutical research has relied on episodic observations because they were practical to collect and analyse at scale. But disease unfolds continuously, and patients experience symptoms, treatment effects, and changes in quality of life between clinical encounters.

As AI makes increasingly complex health datasets more interpretable, pharmaceutical organisations have an opportunity to develop a richer understanding of treatment response, unmet need, and the everyday realities of living with chronic disease.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/information-technology/from-snapshots-to-movies

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

05/10/2026

𝐄𝐥𝐞𝐜𝐭𝐫𝐨𝐧𝐢𝐜 𝐋𝐨𝐠𝐬: 𝐓𝐡𝐞 𝐍𝐞𝐱𝐭 𝐏𝐡𝐚𝐬𝐞 𝐨𝐟 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐨𝐧 𝐌𝐚𝐭𝐮𝐫𝐢𝐭𝐲 𝐢𝐧 𝐏𝐡𝐚𝐫𝐦𝐚

In Pharma Focus Asia – Issue 64, Pavan Pasupulati, Vice President – Product Excellence, Manufacturing, Caliber Technologies, explores how electronic logs are evolving beyond compliance and data integrity to improve ex*****on across pharmaceutical manufacturing operations.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How electronic logs have strengthened traceability, standardization, data integrity, and inspection readiness
• Why digital documentation does not always translate into faster or simpler shop-floor ex*****on
• The impact of ex*****on friction, configurability challenges, and visibility gaps on manufacturing operations
• What the next generation of electronic log platforms must deliver to support faster ex*****on without compromising compliance

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Electronic logs have established a stronger digital foundation for pharmaceutical manufacturing, but the next phase of maturity is about more than capturing data correctly. It is about helping people complete tasks more efficiently, identify bottlenecks earlier, and move work forward with less friction.

As manufacturing operations become increasingly digital, ex*****on readiness is emerging as a critical measure of operational excellence. Modern electronic log platforms can help connect creation, ex*****on, monitoring, and review while maintaining the control and traceability required in regulated environments.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/manufacturing/electronic-logs-the-next-phase

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

03/10/2026

𝐌𝐚𝐱𝐢𝐦𝐢𝐬𝐢𝐧𝐠 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐄𝐧𝐠𝐚𝐠𝐞𝐦𝐞𝐧𝐭 𝐢𝐧 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐓𝐫𝐢𝐚𝐥𝐬

In Pharma Focus Asia – Issue 64, Charlotta Norgaard, Founder and CEO, Patient in Research, explores why early patient involvement is becoming a strategic imperative for Asian pharma and how meaningful patient engagement can reshape clinical research around real patient needs.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why involving patients early in clinical trial planning can improve protocol design, recruitment, retention, and trial feasibility
• How patient insights can help identify treatment burdens, accessibility challenges, cultural considerations, and practical barriers before trials begin
• The role of patients in protocol design, endpoint selection, recruitment communication, digital trial design, and diversity and inclusion
• How patient-centred research can contribute to recruitment efficiency, data quality, regulatory alignment, and market access
• The importance of moving beyond token consultation toward genuine patient partnership, influence, accountability, and fair recognition of patient expertise

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Patient engagement is increasingly becoming an integral part of clinical research strategy rather than a separate ethical initiative. Involving patients before a clinical trial begins can help sponsors understand the realities of participation and design studies that are more feasible, inclusive, and relevant to the people they are intended to serve.

The article also highlights the importance of measuring the impact of engagement through both operational indicators and qualitative outcomes such as trust, transparency, collaboration, and long-term relationships with patient communities.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/clinical-trials/maximising-patient-engagement-in-clinical-trials

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

01/10/2026

𝐋𝐨𝐧𝐠-𝐚𝐜𝐭𝐢𝐧𝐠 𝐈𝐧𝐣𝐞𝐜𝐭𝐚𝐛𝐥𝐞 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬

In Pharma Focus Asia – Issue 64, Nadina Zulbeari, Mathias Dam Mønster Sørensen, and René Holm from the Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, explore recent developments in suspension-based long-acting injectable formulations and their potential to transform sustained drug delivery.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• How long-acting injectable formulations can maintain therapeutic drug concentrations for weeks or months after a single administration
• Why suspension-based LAIs offer a practical and versatile approach to sustained drug delivery
• How particle size, crystal form, and dissolution kinetics govern drug release from suspension depots
• The role of surfactants, viscosity modifiers, and other excipients in suspension stability and performance
• How particle engineering, media milling, and high-pressure homogenisation support formulation development

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Long-acting injectable formulations can reduce dosing frequency while helping address medication adherence challenges associated with chronic treatment. Suspension-based systems are particularly attractive because controlled dissolution of poorly soluble drug particles can provide sustained release without relying entirely on complex biodegradable carrier systems.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/research-development/long-acting-injectable-formulations

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

30/09/2026

𝐖𝐡𝐲 𝐏𝐡𝐚𝐫𝐦𝐚'𝐬 𝐒𝐚𝐟𝐞𝐭𝐲 𝐍𝐞𝐭 𝐌𝐮𝐬𝐭 𝐅𝐨𝐥𝐥𝐨𝐰 𝐭𝐡𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞 𝐇𝐨𝐦𝐞

The pharmaceutical supply chain has become increasingly sophisticated at protecting medicines before they reach the patient. But what happens after the medicine leaves the pharmacy or arrives at the patient's doorstep?

𝐀𝐮𝐭𝐡𝐨𝐫: Barbara Van Rymenam, Senior Director, Healthcare, Avery Dennison

Barbara Van Rymenam works with leaders across pharmaceutical, medical device and healthcare organisations, focusing on digital product identities, patient safety, trusted data and innovative solutions for highly regulated environments.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Extending medicine safety and traceability beyond the pharmacy
• Growing patient concerns around counterfeit and substandard medicines
• The impact of medication non-adherence on patients and healthcare systems
• Using RFID and NFC-enabled packaging for authentication and digital guidance
• Connecting patients with medication information, reminders and pharmacists
• Addressing different digital communication preferences across markets
• Building a connected safety architecture that reaches the patient's home

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬: As healthcare delivery increasingly shifts toward home-based and direct-to-patient models, the pharmaceutical safety net needs to extend beyond the point of dispensing. Connected packaging and digital product identities could help bridge the gap between supply-chain assurance and patient-level confidence, information and adherence.

🔗 https://www.pharmafocusasia.com/articles/why-pharmas-safety-net-must-follow-the-medicine-home

RFID pharmaceutical packaging extends supply chain traceability to patients, supporting medication authentication, adherence and safer home-based care.

30/09/2026

𝐂𝐨𝐦𝐩𝐥𝐞𝐱 𝐉𝐨𝐮𝐫𝐧𝐞𝐲 𝐟𝐫𝐨𝐦 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐭𝐨 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐈𝐦𝐩𝐚𝐜𝐭

In Pharma Focus Asia Magazine – Issue 64, Varun Sethi, CEO, Clinigen, explores why developing an innovative medicine is only the first step in delivering meaningful patient impact.

The article examines how pharmaceutical and biotech companies can integrate access planning, evidence generation, operational readiness and geographic considerations earlier into the development and commercialisation journey to help close the gap between regulatory approval and real-world patient access.

𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:
• Why innovative medicines require more than regulatory approval to achieve real-world patient impact
• How access planning can be integrated into the drug development and commercialisation strategy from an earlier stage
• How advanced therapies may require specialist treatment centres, diagnostics, supply chains and patient coordination
• Why geographic differences in regulatory, reimbursement and healthcare infrastructure require tailored access strategies
• The unique access and commercialisation challenges faced by emerging biotech companies
• Why partnerships and targeted outsourcing can help biotechs access specialist capabilities without building every function internally
• How treating access as a strategic design principle can support more effective launch ex*****on and sustainable patient access

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
Regulatory approval does not automatically guarantee that a medicine can be funded, delivered or accessed by patients. Integrating access, evidence generation, supply planning and healthcare-system readiness into development strategy earlier can help organisations better prepare for the realities of bringing innovative therapies to patients across different markets.

𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞:
https://www.pharmafocusasia.com/strategy/complex-journey-from-innovation

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐀𝐬𝐢𝐚 – 𝐈𝐬𝐬𝐮𝐞 𝟔𝟒:
https://www.pharmafocusasia.com/latest-ebook

29/09/2026

𝐁𝐄𝐍𝐄𝐎: 𝐑𝐚𝐢𝐬𝐢𝐧𝐠 𝐭𝐡𝐞 𝐒𝐭𝐚𝐧𝐝𝐚𝐫𝐝 𝐟𝐨𝐫 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐚𝐧𝐝 𝐍𝐮𝐭𝐫𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐒𝐚𝐜𝐡𝐞𝐭 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧

How can formulators balance patient-friendly dosing with efficient processing and reliable product performance? BENEO introduces galenIQ™ 721, a plant-based diluent designed to support the evolving needs of pharmaceutical and nutraceutical sachet formulations.

𝐊𝐞𝐲 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬:
• Excellent flowability for efficient processing
• Clean processing with low dust
• Sweet taste for patient-friendly formulations
• Flexible formulation design
• Suitable for direct-to-mouth powders and products taken with water

𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬:
galenIQ™ 721 can support a range of pharmaceutical and nutraceutical concepts, including formulations containing ingredients such as vitamins and probiotics.

𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:
As sachets continue to grow as convenient, single-dose formats, formulation performance needs to extend beyond the patient experience. galenIQ™ 721 is designed to help bring flowability, processing efficiency, taste and formulation flexibility together.

🔗 𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐭𝐡𝐞 𝐒𝐚𝐜𝐡𝐞𝐭 𝐅𝐨𝐫𝐦𝐮𝐥𝐚𝐭𝐢𝐨𝐧 𝐁𝐞𝐧𝐞𝐟𝐢𝐭𝐬:
https://industry.pharmafocusasia.com/clientemailblast/1790579577-Beneo.html